Risk factors
enGene Therapeutics (ENGN) risk factors
Item 1A of every enGene Therapeutics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors90 risks10 new8 dropped15 reworded
Net losses increased to $117.3 million in fiscal 2025 with an accumulated deficit of $372.0 million. Key executive transitions occurred including a CEO change in July 2024 and CMO change in September 2025. A resale registration covers 46.97 million common shares and 6.28 million warrants.
Filed Dec 22, 2025 - FY2024 10-K risk factors88 risks
Clinical-stage biotechnology company dependent on the success of its lead genetic medicine candidate, detalimogene, for NMIBC.
Filed Dec 19, 2024